| Overview |
| bs-3307R |
| NMDAR2B Polyclonal Antibody |
| IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse NMDAR2B |
| 1434-1484/1484 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months. |
| Target |
| 2904 |
| Q13224 |
| Cytoplasm |
| MRD6; NR2B; hNR3; GluN2B; NMDAR2B; Glutamate receptor ionotropic, NMDA 2B; Glutamate [NMDA] receptor subunit epsilon-2; N-methyl D-aspartate receptor subtype 2B; N-methyl-D-aspartate receptor subunit 3; NR3; GRIN2B |
| NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-133 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity). |
| Application Dilution |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |